Previous close | 40.00 |
Open | N/A |
Bid | 0.00 |
Ask | 0.00 |
Strike | 95.00 |
Expiry date | 2024-11-15 |
Day's range | 40.00 - 40.00 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Incyte First […]
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.